Antiviral combined with immune modulation therapy
Antiviral combined with immune modulation therapy has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Mar 16, 2026: “Immune-inflammatory mediators of frailty and long COVID in older adults: a prospective cohort study”.
1 paper studies it1 findingUpdated
“In frail patients, antiviral-immune modulation therapy reduced LCS incidence (17.5% vs 45.0%, P = 0.03)”
- 1 lab in 1 country
- Funders: Government of Jiangsu Province and 2 more
- Humans1
What is Antiviral combined with immune modulation therapy linked with?
1Studies link Antiviral combined with immune modulation therapy with 1 measure, most often long COVID syndrome (1 study).
Long COVID syndrome
downin humans1
1 study
Long COVID syndrome
downin humans1
Antiviral combined with immune modulation therapy lowers the risk of long COVID syndrome in humans (17.5% vs 45.0%, P = 0.03).
“In frail patients, antiviral-immune modulation therapy reduced LCS incidence (17.5% vs 45.0%, P = 0.03)”
Humansin frail older COVID-19 patients
Immune-inflammatory mediators of frailty and long COVID in older adults: a prospective cohort study
BMC geriatrics
Latest
1 paper in 12 monthsBMC Geriatrics
Immune-inflammatory mediators of frailty and long COVID in older adults: a prospective cohort study
Cohort study of 145 peopleImmune response